A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)
Clinical trial NCT06122649 · COMPLETED
Trial details
- NCT number
- NCT06122649
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-27
- Primary completion
- 2025-02-28
- Enrollment
- 203
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.